OVERVIEW
CureVac is a biopharmaceutical company pioneering the direct therapeutic application of messenger RNA (mRNA) the biomolecule that physically transfers genetic information from the nucleus to the cellular protein production machinery.
Building on a unique body of knowledge in RNA research, design and cGMP production, the Company has established a range of proprietary technologies. These include: RNActive® for the design of modified and formulated mRNA targeting a broad range of therapeutic applications, RNAdjuvant® for the use of RNA as an immune stimulant, PUREmessenger® for the GMP-production of long-chain mRNA up to 15.000 nt.
Based on these technologies, the Company is building a growing pipeline of innovative product candidates.
CureVac develops tumor immunotherapies based on its RNActiveŽ technology for the treatment of prostate cancer and non-small cell lung cancer (NSCLC). The first Phase I/IIa trial in prostate cancer began in December 2008 in Europe, a second trial was started in USA in May 2009. A similar trial in NSCLC began in 2009.
The Company was spun off from Tübingen University in 2000 and has secured approximately €38 million in private equity. Key investor is the dievini Hopp BioTech holding GmbH&Co. KG, a venture capital firm owned by the Hopp family. Mr. Dietmar Hopp is a co-founder of Walldorf-based software house SAP AG.
